Available online 11 September 2022, 106673

C. albicans biofilm-associated infections pose a huge clinical challenge.

C. albicans biofilm is highly resistant to antifungal drugs and the host immune system.

Preventing the formation of C. albicans biofilms is an effective strategy to resist C. albicans biofilm infections.

Current antifungal biofilm drugs are limited and have many shortcomings. Therefore, developing novel therapeutics strategies for C. albicans biofilm infections is of great clinical.

Targeting can be achieved by novel drug delivery systems, which is a strategy to increase the penetration of drugs.

Candida albicans, a fungal pathogen, can form biofilms on medical devices and host tissue, resulting in serious life-threatening infections. Because those fungal biofilms are inherently resistant to traditional antifungal therapies and the host immune system, biofilm-associated infections pose a huge clinical challenge. In this review, we summarize the most important insights into C. albicans biofilm-associated antifungal drug resistance mechanisms and immune evasion strategies. Moreover, we discuss the strategies of antifungal drugs to combat these processes, providing further evidence for novel drugs and clinical therapies.

Candida albicans

biofilms

resistance

immune escape

therapeutic foresight

© 2022 Published by Elsevier Ltd.